AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q4 FY21 results · Jan–Mar 2021
AstraZeneca Pharma India reported revenue from operations of ₹210.26 crore (up 7.9% from Q4 FY20) and net profit of ₹27.28 crore (up 184.8% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a standalone basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 210.26 | 194.90 | +7.9% | 200.25 | +5.0% |
| Other income | 2.55 | 3.38 | −24.4% | 2.93 | −12.8% |
| Total income | 212.81 | 198.28 | +7.3% | 203.18 | +4.7% |
| Profit before tax | 36.84 | 13.35 | +175.9% | 28.30 | +30.2% |
| Net profit for the period | 27.28 | 9.58 | +184.8% | 21.05 | +29.6% |
| EPS, basic (₹) | 10.91 | 3.83 | +184.8% | 8.42 | +29.6% |
| Net margin (%) | 13.0 | 4.9 | 10.5 |
Standalone
- Filed with BSE
- 26 May 2021, 12:32 IST
- Board meeting
- 25 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE